Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa in trauma
NCT04588311Phase 3Recruiting
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
- Start
- Nov 2020
- Primary completion
- Dec 2026
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 9
01
Overview
A Phase 3 trial of epoetin alfa in traumatic injury, sponsored by Australian and New Zealand Intensive Care Research Centre. Started Nov 2020; status: recruiting.
02
Drugs
epoetin alfa
03
Conditions
traumatic injury
Beyond the preview
Go deeper on NCT04588311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04588311.